EAM Investors’s Editas Medicine EDIT Stock Holding History

EAM Investors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-30,895	Closed	-$2.17M	–	366
2020 Q4	$2.17M	Buy	+30,895	New	+$1.27M	0.35%	94

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM Investors's EDIT Position: Q1 2021 in Review

EAM Investors sold out of Editas Medicine (EDIT) in Q1 2021, closing a stake of 30,895 shares — an estimated $2.17M sold.

EAM Investors first reported a position in EDIT in Q4 2020 and held it in 1 quarter. The position peaked at $2.17M in Q4 2020. 312 funds tracked by Wall St. Rank hold EDIT as of Q1 2021.

EAM Investors reported no remaining Editas Medicine position as of Q1 2021 after selling out during the quarter.
EAM Investors sold 30,895 Editas Medicine shares in Q1 2021, an estimated $2.17M.
EAM Investors first reported a position in Editas Medicine in Q4 2020 and held it in 1 quarter.
EAM Investors's Editas Medicine position peaked at $2.17M in Q4 2020.
312 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.